The prospective, multicenter cohort study EuroSIDA has previously reported on predictors and outcomes of anemia in patients infected with human immunodeficiency virus. In a Cox proportional-hazards model with serial measures of CD4 + cell count, plasma viral load, and degrees of anemia fitted as time-dependent variables, the relative hazard of death increased markedly for patients with anemia versus no anemia. A clinical scoring system was developed and validated for patients receiving highly active antiretroviral therapy using the most recent laboratory measures. Mild and severe anemia were independently ( ) associated with clinical P ! .01 disease progression, with a relative hazard of disease progression of 2.2 (95% confidence interval [CI], 1.6-2.9) and 7.1 (95% CI, 2.5-20.1), respectively, compared with patients with no anemia. The mechanisms underlying why hemoglobin is such a strong prognostic marker and whether correction of anemia itself results in a better prognosis remain to be determined.
AIDS, the pattern of change in hemoglobin (Hb) levels during HIV disease has not been characterized. Earlier studies tended to rely on single measurements of Hb and CD4 + cell counts. In addition, to our knowledge, the combined prognostic value of Hb levels, CD4 + cell counts, and viral load has not been previously evaluated. The EuroSIDA study is a large, observational, prospective, cohort study of HIV-positive patients from outpatient treatment centers across Europe [6] . The study began in 1994 and is designed to allow examination of patient characteristics, laboratory and disease variables, treatments, outcomes, and relationships among these factors over time. A recent analysis sought to compare the rate of changes in Hb over time in patients who died with the rate in patients who did not die [6] . Another goal of this analysis was to evaluate the prognostic value of Hb and CD4 + cell counts in combination [6] . In addition, because there were data on viral load in a substantial subgroup of patients, the joint prognostic value of the latest Hb value, viral load, and CD4 + cell count was determined [6] . Among patients from EuroSIDA who received HAART, a scoring system to quantify the immediate risk of clinical disease progression also has been developed [15] .
ANEMIA AND SURVIVAL

Methods.
The EuroSIDA study is a prospective European study of patients with HIV in 70 centers across Europe; the study now includes sites in Argentina and Israel. Details of the study have been published elsewhere [6] . In brief, centers provided data on consecutive patients seen in the outpatient clinic from 2 May 1994 until a predefined number of patients were enrolled from each center. Patients were required to have a prebooked clinic appointment and to be 116 years old. This cohort of 3116 patients was defined as the EuroSIDA I cohort. Enrollment of a second cohort of 1365 patients began in December 1995. In April 1997, a further 2839 patients were recruited; these patients were defined as the EuroSIDA III cohort. Cohort IV, comprising 1225 patients, was enrolled from April 1999, and an additional cohort, cohort V, 1256 patients, was recruited from September 2001. For cohorts I-III, eligible patients were those with a CD4 + cell count of !500 cells/mm 3 in the previous 4 months, a booked clinic appointment, and an age of 116 years at the time of enrollment. The CD4 + count restriction was removed for cohorts IV and V.
Information from patient notes was provided on a standardized data collection form at baseline and every 6 months thereafter. At each follow-up visit, details on all CD4 + counts measured since last follow-up and viral load measurements were collected. Height, weight, Hb level, and other laboratory measures were also routinely collected. For each patient, the date of starting and stopping each antiretroviral drug was recorded, as was the use of drugs for prophylaxis against opportunistic infections. Dates of diagnosis of all AIDS-defining illnesses were also recorded, including diagnoses made after the initial diagnosis. We used the 1993 clinical definition of AIDS from the Centers for Disease Control and Prevention (i.e., patients with a CD4 + count of !200/mm 3 and no clinical diagnosis would not be classified as having AIDS).
Patients were classified as having severe anemia (Hb !8 g/dL for men and women), mild anemia (Hb 8-14 g/dL for men, Hb 8-12 g/dL for women), or no anemia (Hb 114 g/dL for men, Hb 112 g/dL for women). The change in median Hb level from enrollment was calculated by means of linear interpolation at each 6-month time point [6] . A linear regression model was used to estimate the annual rate of change in Hb after enrollment among patients with at least 3 Hb measurements before death. Multiple linear regression was used to determine which factors were associated with the rate of change in Hb [6] . Standard Kaplan-Meier techniques were used to investigate the proportions of patients who died among the 3 groups [6] . Cox proportional-hazards model analyses were performed by serial measures of CD4 + cell count, plasma viral load, and Hb fitted as time-dependent variables to determine the relationship among prognostic markers for the risk of death [6] .
Results. Among the patients enrolled in the first 3 cohorts of the study, 93% had an Hb and CD4 + cell count measurement at enrollment and were included in the analysis [6] . Seventynine percent of patients were men, and 90% were white [6] . The most common risk factors for HIV infection were homosexuality (46%), intravenous drug use (25%), and heterosexuality (22%) [6] . Thirty-one percent of patients received a clinical diagnosis of AIDS [6] . The median Hb level among all patients was 13.1 g/dL. However, there were significant differences between demographic groups at recruitment with respect to Hb levels. For example, a significantly higher baseline Hb level was associated with men versus women (13.5 g/dL vs. 12.2 g/dL;
), P ! .0001 white versus nonwhite (13.2 g/dL vs. 12.3 g/dL, ), and P ! .0001 no previous AIDS diagnosis versus previous AIDS diagnosis (13.5 g/dL vs. 12.4 g/dL;
) [6] . P ! .0001 At recruitment to the study, 40.4% of patients had a normal Hb level, 58.2% had mild anemia, and 1.4% had severe anemia [6] . Those with severe anemia were significantly more likely to have a CD4 + count р50 cells/mL ( ) [6] . In addition, those P ! .001 with either mild or severe anemia were significantly more likely to have ever received zidovudine or to have been diagnosed with AIDS in the previous 6 months ( ) [6] . P ! .001 There were 3008 patients with у3 serial Hb measurements during follow-up for whom a linear regression model could be used to estimate an annual change in Hb levels [6] . Among all of these patients, the yearly change in Hb was minimal (+0.06 g/dL), with 51.8% of patients having an increase in Hb level (figure 1) [6] . Among those who remained alive during followup, there was a median annual increase in Hb of 0.25 g/dL, with 58.1% of patients having increasing Hb levels [6] . However, those who died during follow-up had a median annual decrease in Hb level of 2.41 g/dL, a difference that was statistically significant ( ) [6] . Only 23.9% of patients who died had increasing P ! .0001 Hb levels [6] . Patients who died also had a significantly faster rate of decline in Hb levels ( ) after adjustment for dem-P ! .0001 ographic variables, baseline CD4 + cell count, Hb level, and AIDS status at recruitment [6] . No association was evident between Hb level at death and cause of death [6] . Figure 2 shows the Kaplan-Meier survival estimates for patients according to severity of anemia at enrollment. The 12-month death rates for patients without anemia, those with mild anemia, or those with severe anemia were 3.1%, 15.9%, and 40.8%, respectively ( ) [6] . Because there were fewer P ! .0001 than 20 patients remaining alive after 12 months in the severe anemia group, the curve for this group was truncated [6] .
Hb level and CD4 + cell count were both strongly correlated with the risk of death in both univariate and multivariate Cox proportional-hazards models ( ) [6] . Both factors were P ! .0001 found to be independently associated with the risk of death in a multivariate model adjusted for demographic factors such as age, sex and risk group, treatment, and AIDS status [6] . For each 1-g/dL decrease in Hb level, the relative hazard of death Kaplan-Meier estimate of survival according to baseline severity of anemia at enrollment [6] . The difference between the 3 groups was highly statistically significant ( ). *, Hemoglobin (Hb) 8-14 g/dL for males, 8-12 g/dL for females; † Hb !8 g/dL for males and females. Adapted P ! .0001 with permission from Mocroft A, Kirk O, Barton SE, et al, for the EuroSIDA Study Group. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients across Europe. AIDS 1999; 13:943-50 [6] .
(RHD) was 1.39 (95% CI, 1.34-1.43;
). The RHD P ! .0001 associated with a 50% decrease in CD4 + cell count was 1.36 (95% CI, 1.31-1.41;
) [6] .
The multivariate Cox model also was conducted using the 3 anemia severity categories with serial measures of CD4 + cell counts and Hb values as time-dependent variables. Figure 3 shows the RHD rates for these categories [6] . In this model, the RHD values are expressed relative to a person with a CD4 + cell count 1200 cells/mL and a normal Hb level [6] . The RHD increases exponentially either as the CD4 + cell count decreases or as anemia develops [6] . For example, among patients with a CD4 + cell count 1200 cells/mL, the RHD was 29-fold higher for those with severe anemia compared with those without anemia [6] . Notably, the prognostic value of Hb level and CD4 + cell count for the risk of death was additive. For patients with both severe anemia and a CD4 + cell count р50 cells/mL, the relative risk of death was 90-fold higher than for those with a normal Hb level and a CD4 + cell count 1200 cells/mL [6] . Among 4707 patients with at least 1 prospective measurement of viral load, there were 164 deaths [6] . The logarithm of viral load also was included in Cox proportional-hazards models as a time-dependent covariate [6] . Despite fewer patients and end points, Hb level remained a significant prognostic marker for death after adjustment for CD4 + cell count and viral load [6] . In a multivariate model, after adjustment, the RHD associated with a 1-g/dL decrease in Hb was 1.57 (95% CI, 1.41-1.75;
The use of HAART regimens appeared to have an effect on the anemia status of the 1624 patients in the study who initiated HAART during the prospective follow-up period [6] . Among these patients, 34.5% had no anemia before the initiation of HAART, whereas 64.0% had mild anemia and 1.5% had severe anemia [6] . After 6 months of HAART therapy, these proportions had changed to 46.8%, 52.0%, and 1.2%, respectively. After 12 months of HAART, the proportions of patients with no, mild, or severe anemia were 53.5%, 45.6%, and 0.6%, respectively [6] .
CLINICAL DISEASE PROGRESSION SCORING SYSTEM
Although a number of risk factors for clinical progression of disease among HIV-infected patients have been identified, these risk factors are poorly defined. It is expected that the most recently measured values of laboratory prognostic markers will have higher predictive value than those obtained at the start of HAART because they are more likely to reflect the current response to therapy. Thus, a scoring system of parameters that predict the immediate risk of clinical progression among patients receiving HAART was developed that used the most recently obtained laboratory values from a cohort of patients in the EuroSIDA study receiving HAART [15] .
Methods. Cox proportional-hazards models were used to determine the prognostic factors associated with clinical progression of disease (AIDS or death) and to derive a simple score and grading system [15] . Patients were categorized according to their most recent laboratory values for CD4 + cell count, viral load, and Hb. The CD4 + cell count cutoffs were !50, 50-200, and 1200 cells/mL, whereas the viral load cutoffs were !500, 500-9999, and 110,000 copies/mL. The Hb cutoff points were the same as those defined in the previous anemia and survival analysis [15] . Clinical status was included as a fixed categorical variable at the start of HAART: no AIDS, AIDS within the past 12 months of start of HAART (all diagnoses except progressive multifocal leukoencephalopathy and non-Hodgkin's lymphoma), and severe AIDS (progressive multifocal leukoencephalopathy and non-Hodgkin's lymphoma).
Clinical events were recorded among 2027 patients from the EuroSIDA study who had CD4 + cell count and HIV viral load measurements before and after the initiation of HAART [15] . As of February 2001, there were 200 clinical events among these patients (9.9% incidence): 59 deaths, 94 instances of a first AIDS-defining illness, and 47 cases of progression to a new AIDSdefining event [15] . The most common AIDS-defining events were non-Hodgkin's lymphoma (18%), esophageal candidiasis (15%), pulmonary tuberculosis (10%), Kaposi's sarcoma (8%), HIV wasting syndrome (6%), and Pneumocystis carinii pneumonia (5%) [15] . Twelve months after the initiation of HAART, 5.1% of patients (95% CI, 4.1-6.1) had experienced disease progression [15] . The proportions of patients experiencing disease progression after 24 and 36 months were 8.1% (95% CI, 6.8-9.4) and 11.6% (95% CI, 10.0-13.2), respectively [15] . The most recently measured CD4 + cell count, viral load, and Hb level were all independently related to the risk of disease progression (table 1) . For example, the relative hazard (RH) of progression for patients with a CD4 + cell count of 51-200 cells/ mL was 2.6, increasing to 9.3 for those with a CD4 + cell count р50 cells/mL compared with those with a CD4 + cell count 1200 cells/mL ( for both comparisons) [15] . The RH of pro-P ! .0001 gression for patients with mild and severe anemia was 2.2 ( ) and 7.1 ( ), respectively, compared with P ! .0001 P p .0002 those with a normal Hb [15] . The most recent viral load measurement was a weaker predictor of disease progression, with those with values between 500 and 9999 copies/mL having an RH of 1.3 ( ) and those with a value у10,000 copies/ P p .14 mL having an RH of 1.8 ( ) [15] . Patients who ever P p .001 received a diagnosis of severe AIDS also appeared to have an increased risk of disease progression ( ); however, this RH p 1.9 value did not quite reach statistical significance ( ) [15] . P p .07
On the basis of the RH of progression data, a scoring system for the risk of disease progression was developed (table 2) . Because the CD4 + cell count and Hb level were associated with the highest RH rates, these parameters were assigned the greatest weight in the clinical progression score. A patient's score can be calculated by summing the latest score values for each of the 4 independent risk factors [15] . For example, when this scoring system is used, a patient with a current CD4 + cell count of 80 cells/mL (3 points), a viral load of 5000 copies/mL (1 point), an Hb level of 9 g/dL (2 points), and a diagnosis of Pneumocystis carinii pneumonia 18 months before the initiation of HAART (0 points) would have a score of 6.
The predictability of the scoring system was validated in 2 additional cohorts of patients [15] . The first cohort included 1946 patients from the EuroSIDA study who initiated HAART before recruitment to the EuroSIDA study. The second cohort included 1442 patients from a single clinic in Barcelona who initiated HAART. The characteristics of these 2 validation cohorts were similar to those of the derivation cohort. The RH and relative risk of progression per unit increase in score values derived in these validation cohorts were similar to those seen in the EuroSIDA derivation cohort (figure 4). In general, a single point increase in score was associated with an increased risk of clinical progression of ∼40%. Figure 5 shows the incidence of clinical progression as a function of the disease progression score for all 3 cohorts combined [15] . There was a linear relationship between the disease progression score and development of clinical progression. At a score of 0 points, the incidence rate of clinical progression was 1.0 per 100 personyears of follow-up; the incidence rate increased to 12.0 per 100 person-years of follow-up at a score of 6 points and to 142.0 per 100 person-years of follow-up at a score of у12 points.
SUMMARY
The EuroSIDA study is a large, ongoing, prospective study that currently includes 19800 HIV-infected patients and 130,000 person-years of follow-up. An analysis that used data from the EuroSIDA study was the first attempt to document the pattern of Hb levels over time in HIV-infected patients [6] . Overall, women, nonwhites, and those with low CD4 + cell counts and/ or with a recent AIDS-defining illness had lower Hb levels than patients without these characteristics. An important finding was that there was a gradual and continual decrease in Hb levels over time among those who died during follow-up [6] . In contrast, Hb levels remained stable among those who did not die [6] . The results of this EuroSIDA analysis demonstrated that Hb levels are predictive of survival in HIV-infected patients and, for the first time, that Hb, CD4 + cell count, and viral load were all independent prognostic markers [6] . The analysis showed that the risk of death increases dramatically as either Hb levels or CD4 + cell counts or both decline [6] . In addition, the effect of these 2 predictive factors was additive [6] . A similar prognostic value for AIDS also was found [6] . The mechanisms underlying why Hb is such a strong prognostic marker are unknown. Thus, it remains to be determined whether the presence of anemia is causally related to the clinical outcome of patients. There also was evidence from this analysis that the initiation of HAART was associated with recovery from anemia in many patients [6] , an observation subsequently reported in other studies [16] [17] [18] . However, after 12 months of HAART, mild to moderate anemia is still evident in a substantial proportion of patients. The impact of HAART-induced increases in Hb on patient survival remains to be determined [6] . On the basis of the identification of prognostic markers for the risk of disease progression, a clinical progression scoring system has been developed for HIV-infected patients receiving HAART that uses 4 clinical risk factors (Hb level, CD4 + cell count, viral load, AIDS status). This scoring system is effective for predicting short-term prognosis (i.e., within the next 3-6 months). However, it is unknown whether the determinants for longer-term prognosis are the same as those identified in these analyses. It also is unknown whether the correction of anemia by itself will result in a better clinical outcome. Several cohort studies have identified associations between correction of Hb by various means and better prognosis [4, 12] , although reverse causality may explain these findings. Randomized trials with clinical outcome are required to show a causal link. Nevertheless, the results from cohort studies underscore the significant prognostic value of anemia in HIV-infected patients.
